Novocure has reimbursement win for Optune Lua in Japan

Novocure (Nasdaq:NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved reimbursement for its Optune Lua system.

Optune Lua a wearable, portable medical device, produces alternating electric fields called tumor-treating fields (TTFields). Delivered through non-invasive, wearable arrays, TTFields exert physical forces on the electrically charged components of dividing cancer cells.

Alternating electrical fields target the electrical properties of cancer cells to disrupt processes critical for cancer cell division and survival. This leads to cell death without significantly affecting healthy cells.

Sign up for Blog Updates